Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

JP Morgan Maintains Overweight on e.l.f. Beauty, Raises Price Target to $65

January 13, 9:53 AM

JP Morgan analyst Andrea Teixeira maintains e.l.f. Beauty (NYSE:ELF) with a Overweight and raises the price target from $62 to $65.

January 16, 8:00 AM

Throughout the last three months, 24 analysts have evaluated Target (NYSE:TGT), offering a diverse set of opinions from…

November 9, 4:00 PM

Analysts have provided the following ratings for Jack Henry & Associates (NASDAQ:JKHY) within the last quarter: Bullish Somewhat…

October 7, 5:40 AM

In a recent podcast appearance, Joe Rogan and UFC champion Sean O'Malley discussed the exceptional speed of Tesla's Model X Plaid.